INT165621

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 2008
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 4
Total Number 4
Disease Relevance 4.50
Pain Relevance 0.72

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (TGS1) nucleoplasm (TGS1) small molecule metabolic process (TGS1)
methyltransferase activity (TGS1) nucleus (TGS1) cytoplasm (TGS1)
Anatomy Link Frequency
plasma 2
TGS1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 21 98.88 Very High Very High Very High
rheumatoid arthritis 30 94.68 High High
abdominal pain 2 90.44 High High
cva 8 88.72 High High
Infliximab 1 62.40 Quite High
tolerance 8 5.00 Very Low Very Low Very Low
Angina 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
cINOD 1 5.00 Very Low Very Low Very Low
Rheumatism 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 33 100.00 Very High Very High Very High
Hypertension 13 100.00 Very High Very High Very High
Metabolic Syndrome 13 100.00 Very High Very High Very High
Dyslipidemia /

Combined Dyslipidemia

8 99.30 Very High Very High Very High
INFLAMMATION 22 98.88 Very High Very High Very High
Communicable Diseases 38 98.20 Very High Very High Very High
Disease 23 97.32 Very High Very High Very High
Congenital Anomalies 4 96.12 Very High Very High Very High
Rheumatoid Arthritis 30 94.68 High High
Cardiovascular Disease 15 93.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Prevalence of hypertension, obesity, high TC, low HDL, and high TGs, was 11.7, 4.3, 5.1, 8.3, and 5%, respectively [2].
Negative_regulation (Prevalence) of TGs associated with hypertension, metabolic syndrome and disorder of lipid metabolism
1) Confidence 0.14 Published 2009 Journal Trials Section Body Doc Link PMC2656492 Disease Relevance 1.42 Pain Relevance 0.08
The first clinical trials in patients with LPL deficiency appear promising, with a significant decrease in the levels of plasma TGs observed in the first 3 months following the administration of alipogene tiparvovec, and an increase in local LPL activity and protein levels observed after 6 months.
Negative_regulation (decrease) of TGs in plasma
2) Confidence 0.06 Published 2009 Journal Curr. Opin. Mol. Ther. Section Abstract Doc Link 20072945 Disease Relevance 0.57 Pain Relevance 0.08
The LPLSer(447)X variant is associated with decreased levels of plasma TGs and increased HDL cholesterol concentrations compared with wild-type LPL.
Negative_regulation (decreased) of TGs in plasma associated with disorder of lipid metabolism
3) Confidence 0.05 Published 2009 Journal Curr. Opin. Mol. Ther. Section Abstract Doc Link 20072945 Disease Relevance 0.60 Pain Relevance 0.09
The dyslipidemia is often presented with normal or decreased low-density lipoprotein (LDL) cholesterol, low high-density lipoprotein (HDL) cholesterol, and high triglycerides (TGs) in a manner comparable to inflammatory and infectious diseases in general [12].
Negative_regulation (decreased) of TGs associated with inflammation, communicable diseases and disorder of lipid metabolism
4) Confidence 0.02 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2453753 Disease Relevance 1.76 Pain Relevance 0.47

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox